Introduction: The relationship between carotid artery stenosis (CAS) and ipsilateral silent brain ischemia (SBI) remains unclear, with uncertain therapeutic implications. The present study, part of the TAXINOMISIS project (nr. 755,320), aimed to investigate SBIs in patients with asymptomatic CAS, correlating them with clinical, carotid ultrasonographic data, and CFD analyses. Methods: The TAXINOMISIS clinical trial study (nr. NCT03495830) involved six vascular surgery centers across Europe, enrolling patients with asymptomatic and symptomatic CAS ranging from 50 to 99%. Patients underwent carotid ultrasound and magnetic resonance imaging (MRI), including brain diffusion-weighted, T2-weighted/FLAIR, and T1-weighted sequences. Brain MRI scans were analyzed for the presence of SBI according to established definitions. Ultrasound assessments included Doppler and CFD analysis. Only asymptomatic patients were included in this substudy. Results: Among 195 asymptomatic patients, the mean stenosis (NASCET) was 64.1%. Of these, a total of 33 patients (16.9%) had at least one SBI detected on a brain MRI scan. Specifically, 19 out of 33 patients (57.6%) had cortical infarcts, 4 out of 33 patients (12.1%) had ipsilateral lacunar infarcts, 6 out of 33 patients had (18.2%) subcortical infarcts, 1 out of 33 patients (3.0%) had both cortical and lacunar infarcts, and 3 out of 33 patients (9.1%) both cortical and subcortical infarcts. Patients with SBIs exhibited significantly higher risk factors, including a higher body mass index (28.52 +/- 9.38 vs. 26.39 +/- 3.35, p = 0.02), diastolic blood pressure (80.87 +/- 15.73 mmHg vs. 80.06 +/- 8.49 mmHg, p = 0.02), creatinine levels (93.66 +/- 34.61 mu mol/L vs. 84.69 +/- 23.67 mu mol/L, p = 0.02), and blood triglycerides (1.8 +/- 1.06 mmol/L vs. 1.48 +/- 0.78 mmol/L, p = 0.03). They also had a higher prevalence of cardiovascular interventions (29.6% vs. 13.8%, p = 0.04), greater usage of third/fourth-line antihypertensive treatment (50%vs16%, p = 0.03), and anticoagulant medications (60% vs. 16%, p = 0.01). Additionally, the number of contralateral cerebral infarcts was higher in patients with SBIs (35.5% vs. 13.4%, p < 0.01). Moreover, carotid ultrasound revealed higher Saint Mary's ratios (15.33 +/- 12.45 vs. 12.96 +/- 7.99, p = 0.02), and CFD analysis demonstrated larger areas of low wall shear stress (WSS) (0.0004 +/- 0.0004 m(2) vs. 0.0002 +/- 0.0002 m(2), p < 0.01). Conclusion: The TAXINOMISIS clinical trial provides valuable insights into the prevalence and risk factors associated with SBIs in patients with moderate asymptomatic carotid stenosis. The findings suggest that specific hemodynamic and arterial wall characteristics may contribute to the development of silent brain infarcts.

Kigka, V., Carrozzi, A., Gramegna, L.L., Siogkas, P.K., Potsika, V., Tsakanikas, V., et al. (2024). Silent brain ischemia within the TAXINOMISIS framework: association with clinical and advanced ultrasound metrics. FRONTIERS IN NEUROLOGY, 15, 1-10 [10.3389/fneur.2024.1424362].

Silent brain ischemia within the TAXINOMISIS framework: association with clinical and advanced ultrasound metrics

Carrozzi A.;Gramegna L. L.;Cirillo L.;Manners D. N.;Pini R.;Faggioli G.;
2024

Abstract

Introduction: The relationship between carotid artery stenosis (CAS) and ipsilateral silent brain ischemia (SBI) remains unclear, with uncertain therapeutic implications. The present study, part of the TAXINOMISIS project (nr. 755,320), aimed to investigate SBIs in patients with asymptomatic CAS, correlating them with clinical, carotid ultrasonographic data, and CFD analyses. Methods: The TAXINOMISIS clinical trial study (nr. NCT03495830) involved six vascular surgery centers across Europe, enrolling patients with asymptomatic and symptomatic CAS ranging from 50 to 99%. Patients underwent carotid ultrasound and magnetic resonance imaging (MRI), including brain diffusion-weighted, T2-weighted/FLAIR, and T1-weighted sequences. Brain MRI scans were analyzed for the presence of SBI according to established definitions. Ultrasound assessments included Doppler and CFD analysis. Only asymptomatic patients were included in this substudy. Results: Among 195 asymptomatic patients, the mean stenosis (NASCET) was 64.1%. Of these, a total of 33 patients (16.9%) had at least one SBI detected on a brain MRI scan. Specifically, 19 out of 33 patients (57.6%) had cortical infarcts, 4 out of 33 patients (12.1%) had ipsilateral lacunar infarcts, 6 out of 33 patients had (18.2%) subcortical infarcts, 1 out of 33 patients (3.0%) had both cortical and lacunar infarcts, and 3 out of 33 patients (9.1%) both cortical and subcortical infarcts. Patients with SBIs exhibited significantly higher risk factors, including a higher body mass index (28.52 +/- 9.38 vs. 26.39 +/- 3.35, p = 0.02), diastolic blood pressure (80.87 +/- 15.73 mmHg vs. 80.06 +/- 8.49 mmHg, p = 0.02), creatinine levels (93.66 +/- 34.61 mu mol/L vs. 84.69 +/- 23.67 mu mol/L, p = 0.02), and blood triglycerides (1.8 +/- 1.06 mmol/L vs. 1.48 +/- 0.78 mmol/L, p = 0.03). They also had a higher prevalence of cardiovascular interventions (29.6% vs. 13.8%, p = 0.04), greater usage of third/fourth-line antihypertensive treatment (50%vs16%, p = 0.03), and anticoagulant medications (60% vs. 16%, p = 0.01). Additionally, the number of contralateral cerebral infarcts was higher in patients with SBIs (35.5% vs. 13.4%, p < 0.01). Moreover, carotid ultrasound revealed higher Saint Mary's ratios (15.33 +/- 12.45 vs. 12.96 +/- 7.99, p = 0.02), and CFD analysis demonstrated larger areas of low wall shear stress (WSS) (0.0004 +/- 0.0004 m(2) vs. 0.0002 +/- 0.0002 m(2), p < 0.01). Conclusion: The TAXINOMISIS clinical trial provides valuable insights into the prevalence and risk factors associated with SBIs in patients with moderate asymptomatic carotid stenosis. The findings suggest that specific hemodynamic and arterial wall characteristics may contribute to the development of silent brain infarcts.
2024
Kigka, V., Carrozzi, A., Gramegna, L.L., Siogkas, P.K., Potsika, V., Tsakanikas, V., et al. (2024). Silent brain ischemia within the TAXINOMISIS framework: association with clinical and advanced ultrasound metrics. FRONTIERS IN NEUROLOGY, 15, 1-10 [10.3389/fneur.2024.1424362].
Kigka, V.; Carrozzi, A.; Gramegna, L. L.; Siogkas, P. K.; Potsika, V.; Tsakanikas, V.; Kallmayer, M.; Obach, V.; Riambau, V.; Spinella, G.; Pratesi, G...espandi
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/1001956
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact